Human T cell expansion and experimental autoimmune encephalomyelitis inhibited by Lenaldekar, a small molecule discovered in a zebrafish screen

Journal of Neuroimmunology

Volumn 244, Issue 1-2, 2012, Pages 35-44

  Cusick, Matthew F ^a   Libbey, Jane E ^a   Trede, Nikolaus S ^a   Eckels, David D ^a   Fujinami, Robert S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Compound; Experimental autoimmune encephalomyelitis; Human T cell

Indexed keywords

HEXAMETHONIUM BROMIDE; IMMUNOMODULATING AGENT; LENALDEKAR; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOLYSIS; DISEASE EXACERBATION; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; FEMALE; HUMAN; HUMAN CELL; IC 50; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; HUMANS; HYDRAZONES; LYMPHOCYTE ACTIVATION; MICE; MULTIPLE SCLEROSIS; QUINOLINES; SMALL MOLECULE LIBRARIES; T-LYMPHOCYTES; ZEBRAFISH;

EID: 84857919866     PISSN: 01655728     EISSN: 18728421     Source Type: Journal    
DOI: 10.1016/j.jneuroim.2011.12.024     Document Type: Article

References (49)

1. Ahmed R. Immunological memory against viruses. Semin. Immunol. 1992, 4:105-109.
2. Allegretta M., Nicklas J.A., Sriram S., Albertini R.J. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990, 247:718-721.
3. Ávila-Flores A., Santos T., Rincón E., Mérida I. Modulation of the mammalian target of rapamycin pathway by diacylglycerol kinase-produced phosphatidic acid. J. Biol. Chem. 2005, 280:10091-10099.
4. Barnett L.A., Whitton J.L., Wada Y., Fujinami R.S. Enhancement of autoimmune disease using recombinant vaccinia virus encoding myelin proteolipid protein [published erratum appears in J Neuroimmunol 48:120, 1993]. J. Neuroimmunol. 1993, 44:15-25.
5. Bertsias G.K., Salmon J.E., Boumpas D.T. Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. Ann. Rheum. Dis. 2010, 69:1603-1611.
6. + T cells in multiple sclerosis. J. Immunol. 2004, 172:3893-3904.
7. Börner C., Smida M., Höllt V., Schraven B., Kraus J. Cannabinoid receptor type 1- and 2-mediated increase in cyclic AMP inhibits T cell receptor-triggered signaling. J. Biol. Chem. 2009, 284:35450-35460.
8. Boster A., Edan G., Frohman E., Javed A., Stuve O., Tselis A., Weiner H., Weinstock-Guttman B., Khan O. Intense immunosuppression in patients with rapidly worsening multiple sclerosis: treatment guidelines for the clinician. Lancet Neurol. 2008, 7:173-183.
9. Burns J., Rosenzweig A., Zweiman B., Lisak R.P. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell. Immunol. 1983, 81:435-440.
10. Chou Y.K., Vainiene M., Whitham R., Bourdette D., Chou C.H., Hashim G., Offner H., Vandenbark A.A. Response of human T lymphocyte lines to myelin basic protein: association of dominant epitopes with HLA class II restriction molecules. J. Neurosci. Res. 1989, 23:207-216.
11. Colombetti S., Basso V., Mueller D.L., Mondino A. Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin. J. Immunol. 2006, 176:2730-2738.
12. Corse E., Gottschalk R.A., Allison J.P. Strength of TCR-peptide/MHC interactions and in vivo T cell responses. J. Immunol. 2011, 186:5039-5045.
13. Cusick M.F., Wang S., Eckels D.D. In vitro responses to avian influenza H5 by human CD4 T cells. J. Immunol. 2009, 183:6432-6441.
14. Davis M.M., Boniface J.J., Reich Z., Lyons D., Hampl J., Arden B., Chien Y. Ligand recognition by αβ T cell receptors. Annu. Rev. Immunol. 1998, 16:523-544.
15. Delgoffe G.M., Pollizzi K.N., Waickman A.T., Heikamp E., Meyers D.J., Horton M.R., Xiao B., Worley P.F., Powell J.D. The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2. Nat. Immunol. 2011, 12:295-303.
16. Donia M., Mangano K., Amoroso A., Mazzarino M.C., Imbesi R., Castrogiovanni P., Coco M., Meroni P., Nicoletti F. Treatment with rapamycin ameliorates clinical and histological signs of protracted relapsing experimental allergic encephalomyelitis in Dark Agouti rats and induces expansion of peripheral CD4+CD25+Foxp3+ regulatory T cells. J. Autoimmun. 2009, 33:135-140.
17. Eckels D.D., Tabatabail N., Bian T.-H., Wang H., Muheisen S.S., Rice C.M., Yoshizawa K., Gill J. In vitro human Th-cell responses to a recombinant hepatitis C virus antigen: failure in IL-2 production despite proliferation. Hum. Immunol. 1999, 60:187-199.
18. Eckels D.D., Zhou H., Bian T.H., Wang H. Identification of antigenic escape variants in an immunodominant epitope of hepatitis C virus. Int. Immunol. 1999, 11:577-583.
19. Esposito M., Ruffini F., Bellone M., Gagliani N., Battaglia M., Martino G., Furlan R. Rapamycin inhibits relapsing experimental autoimmune encephalomyelitis by both effector and regulatory T cells modulation. J. Neuroimmunol. 2010, 220:52-63.
20. Fox E.J. Emerging oral agents for multiple sclerosis. Am. J. Manag. Care 2010, 16:S219-S226.
21. Fujinami R.S., von Herrath M.G., Christen U., Whitton J.L. Molecular mimicry, bystander activation, or viral persistence: infections and autoimmune disease. Clin. Microbiol. Rev. 2006, 19:80-94.
22. Germain R.N., Stefanová I. The dynamics of T cell receptor signaling: complex orchestration and the key roles of tempo and cooperation. Annu. Rev. Immunol. 1999, 17:467-522.
23. Gregersen P.K., Silver J., Winchester R.J. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987, 30:1205-1213.
24. Jacobson D.L., Gange S.J., Rose N.R., Graham N.M. Epidemiology and estimated population burden of selected autoimmune diseases in the United States. Clin. Immunol. Immunopathol. 1997, 84:223-243.
25. Kawamura K., McLaughlin K.A., Weissert R., Forsthuber T.G. Myelin-reactive type B T cells and T cells specific for low-affinity MHC-binding myelin peptides escape tolerance in HLA-DR transgenic mice. J. Immunol. 2008, 181:3202-3211.
26. Langenau D.M., Ferrando A.A., Traver D., Kutok J.L., Hezel J.-P.D., Kanki J.P., Zon L.I., Look A.T., Trede N.S. In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:7369-7374.
27. Lannutti B.J., Meadows S.A., Herman S.E.M., Kashishian A., Steiner B., Johnson A.J., Byrd J.C., Tyner J.W., Loriaux M.M., Deininger M., Druker B.J., Puri K.D., Ulrich R.G., Giese N.A. CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 2011, 117:591-594.
28. Libbey J.E., Fujinami R.S. Potential triggers of MS. Results Probl. Cell Differ. 2010, 51:21-42.
29. Makhani N., Gorman M.P., Branson H.M., Stazzone L., Banwell B.L., Chitnis T. Cyclophosphamide therapy in pediatric multiple sclerosis. Neurology 2009, 72:2076-2082.
30. Martin R., Jaraquemada D., Flerlage M., Richert J., Whitaker J., Long E.O., McFarlin D.E., McFarland H.F. Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals. J. Immunol. 1990, 145:540-548.
31. Martin R., Voskuhl R., Flerlage M., McFarlin D.E., McFarland H.F. Myelin basic protein-specific T-cell responses in identical twins discordant or concordant for multiple sclerosis. Ann. Neurol. 1993, 34:524-535.
32. Mathis D., Benoist C. Levees of immunological tolerance. Nat. Immunol. 2010, 11:3-6.
33. Mathis D., Vence L., Benoist C. β-cell death during progression to diabetes. Nature 2001, 414:792-798.
34. Meeker N.D., Smith A.C.H., Frazer J.K., Bradley D.F., Rudner L.A., Love C., Trede N.S. Characterization of the zebrafish T cell receptor β locus. Immunogenetics 2010, 62:23-29.
35. Mercalli A., Sordi V., Ponzoni M., Maffi P., De Taddeo F., Gatti G., Servida P., Bernardi M., Bellio L., Bertuzzi F., Secchi A., Bonifacio E., Piemonti L. Rapamycin induces a caspase-independent cell death in human monocytes. Am. J. Transplant. 2006, 6:1331-1341.
36. Montanaro D., Sanna V., Matarese G., Larby B.B., Racioppi L., Carrieri P.B., Bruno R., Davey N.J., Zappacosta S., Fontana S. The fine specificity of human T cell lines towards myelin basic protein peptides in southern Italian multiple sclerosis patients. Clin. Exp. Immunol. 2001, 123:288-293.
37. Neefjes J.J., Stollorz V., Peters P.J., Geuze H.J., Ploegh H.L. The biosynthetic pathway of MHC class II but not class I molecules intersects the endocytic route. Cell 1990, 61:171-183.
38. Offner H., Sinha S., Burrows G.G., Ferro A.J., Vandenbark A.A. RTL therapy for multiple sclerosis: a Phase I clinical study. J. Neuroimmunol. 2011, 231:7-14.
39. O'Reilly K.E., Rojo F., She Q.-B., Solit D., Mills G.B., Smith D., Lane H., Hofmann F., Hicklin D.J., Ludwig D.L., Baselga J., Rosen N. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 2006, 66:1500-1508.
40. Quah B.J.C., Warren H.S., Parish C.R. Monitoring lymphocyte proliferation in vitro and in vivo with the intracellular fluorescent dye carboxyfluorescein diacetate succinimidyl ester. Nat. Protoc. 2007, 2:2049-2056.
41. Sabatini D.M. mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer 2006, 6:729-734.
42. Schmelzle T., Hall M.N. TOR, a central controller of cell growth. Cell 2000, 103:253-262.
43. Tabatabai N.M., Bian T.-H., Rice C.M., Yoshizawa, Gill J., Eckels D.D. Functionally distinct T-cell epitopes within the hepatitis C virus non-structural 3 protein. Hum. Immunol. 1999, 60:105-115.
44. Tisch R., McDevitt H. Insulin-dependent diabetes mellitus. Cell 1996, 85:291-297.
45. Tranquill L.R., Cao L., Ling N.C., Kalbacher H., Martin R.M., Whitaker J.N. Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients. Mult. Scler. 2000, 6:200-205.
46. Tsunoda I., Kuang L.-Q., Tolley N.D., Whitton J.L., Fujinami R.S. Enhancement of experimental allergic encephalomyelitis (EAE) by DNA immunization with myelin proteolipid protein (PLP) plasmid DNA. J. Neuropathol. Exp. Neurol. 1998, 57:758-767.
47. Valli A., Sette A., Kappos L., Oseroff C., Sidney J., Miescher G., Hochberger M., Albert E.D., Adorini L. Binding of myelin basic protein peptides to human histocompatibility leukocyte antigen class II molecules and their recognition by T cells from multiple sclerosis patients. J. Clin. Invest. 1993, 91:616-628.
48. von Herrath M.G., Fujinami R.S., Whitton J.L. Microorganisms and autoimmunity: making the barren field fertile?. Nat. Rev. Microbiol. 2003, 1:151-157.
49. Zhang J., Markovic-Plese S., Lacet B., Raus J., Weiner H.L., Hafler D.A. Increased frequency of interleukin 2-responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 1994, 179:973-984.